Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0DZ3X
|
||||
| Former ID |
DAP000198
|
||||
| Drug Name |
L-Proline
|
||||
| Synonyms |
Carboxypyrrolidine; Pro; Prolina; Proline; Prolinum; Prolina [Spanish]; Prolinum [Latin]; CB 1707; L-Prolin; PRO (IUPACabbreviation); Proline (USP); Proline (VAN); Proline [USAN:INN]; H-Pro-OH; L-Proline (JAN); L-Proline-15N; L-alpha-Pyrrolidinecarboxylic acid; L-Proline, labeled with carbon-14; L-Pyrrolidine-2-carboxylic acid; L-(-)-Proline; L-(2,3-3H)Proline; (-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (L)-PROLINE; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Dietary supplement
|
||||
| Formula |
C5H9NO2
|
||||
| InChI |
InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
|
||||
| InChIKey |
ONIBWKKTOPOVIA-BYPYZUCNSA-N
|
||||
| CAS Number |
CAS 147-85-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3448, 608065, 838056, 841800, 3135874, 4253464, 6436528, 6436535, 6436537, 7847103, 7887166, 7890050, 8144250, 10248984, 10508477, 14710669, 15146482, 15194368, 17435868, 24882005, 24887885, 24887886, 24898097, 24898677, 24898986, 24901637, 24902491, 41102174, 46223069, 46504839, 46506858, 49856395, 50108816, 57288676, 57346151, 57652885, 57652886, 57654568, 77943168, 81044534, 81067296, 85164895, 85182322, 85201946, 87574669, 92298421, 92710581, 96021916, 96100167, 99206182
|
||||
| ChEBI ID |
ChEBI:17203
|
||||
| Target and Pathway | |||||
| Target(s) | Peptidyl-prolyl cis-trans isomerase B | Target Info | Binder | [536004] | |
| Peptidyl-prolyl cis-trans isomerase A | Target Info | Binder | [537008] | ||
| Pathway Interaction Database | Syndecan-1-mediated signaling events | ||||
| PathWhiz Pathway | Retinol Metabolism | ||||
| Reactome | Collagen biosynthesis and modifying enzymesR-HSA-114608:Platelet degranulation | ||||
| Uncoating of the HIV Virion | |||||
| Budding and maturation of HIV virion | |||||
| Integration of provirus | |||||
| Early Phase of HIV Life Cycle | |||||
| Minus-strand DNA synthesis | |||||
| Plus-strand DNA synthesis | |||||
| Binding and entry of HIV virion | |||||
| Assembly Of The HIV Virion | |||||
| APOBEC3G mediated resistance to HIV-1 infection | |||||
| Basigin interactions | |||||
| WikiPathways | Collagen biosynthesis and modifying enzymes | ||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in leukocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBaseWP2746:Signaling by the B Cell Receptor (BCR) | |||||
| Host Interactions of HIV factors | |||||
| HIV Life Cycle | |||||
| JAK/STAT | |||||
| Cell surface interactions at the vascular wall | |||||
| References | |||||
| Ref 536004 | Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803. | ||||
| Ref 540275 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3314). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.